Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Modern antiematogenic therapy from 5-HT3 to NK-1 antagonists

Best of ASCO® Miami 2016

8 - 10 Jul 2016

Published: 25 Jul 2016

Views: 2889

Rating:

Save

Dr Sayeh Lavasani - Memorial Cancer Institute, Hollywood, Florida, USA

Dr Lavasani speaks with ecancertv at the Best of ASCO 2016 about limiting the risk of nausea as a result of chemotherapy.

She describes results from international teams, including adjuvant rolapitant and the impact of reduced dexamethasone exposure.

Related Videos

Genomic testing: Awareness and effective communication between healthcare...

Prof Richard Simcock and Antonella Cardone

Genomic testing: Awareness and effective communication between healthcare professionals and patients ( Prof Richard Simcock and Antonella Cardone )

The Vietnam National Cancer Institute’s efforts in improving cancer care in...

Dr Thanh Huong Tran Thi - Director, Vietnam National Cancer Institute

The Vietnam National Cancer Institute’s efforts in improving cancer care in Vietnam ( Dr Thanh Huong Tran Thi - Director, Vietnam National Cancer Institute )

The Southeast Asian Breast Cancer Symposium; background, aims and successes

Carolyn Taylor - Executive Director, Global Focus on Cancer

The Southeast Asian Breast Cancer Symposium; background, aims and successes ( Carolyn Taylor - Executive Director, Global Focus on Cancer )

The current status of multiple myeloma diagnosis and treatment

Dr Patricio Duarte - Instituto Universitario CEMIC, Buenos Aires, Argentina

The current status of multiple myeloma diagnosis and treatment ( Dr Patricio Duarte - Instituto Universitario CEMIC, Buenos Aires, Argentina )

The use of IORT at Universitätsmedizin Mannheim hospital

Dr Elena Sperk - Universitätsmedizin Mannheim, Mannheim, Germany

The use of IORT at Universitätsmedizin Mannheim hospital ( Dr Elena Sperk - Universitätsmedizin Mannheim, Mannheim, Germany )

Overview of the management of HER2-low breast cancer patients

Prof Hope Rugo - University of California San Francisco, San Francisco, USA

Overview of the management of HER2-low breast cancer patients ( Prof Hope Rugo - University of California San Francisco, San Francisco, USA )

HER2-low mBC patients report preserved QOL with trastuzumab deruxtecan

Prof Naoto Ueno - The University of Texas MD Anderson Cancer Center, Houston...

HER2-low mBC patients report preserved QOL with trastuzumab deruxtecan ( Prof Naoto Ueno - The University of Texas MD Anderson Cancer Center, Houston, USA )

Tumour-infiltrating lymphocyte treatment for advanced melanoma

Dr John Haanen - Netherlands Cancer Institute, Amsterdam, Netherlands

Tumour-infiltrating lymphocyte treatment for advanced melanoma ( Dr John Haanen - Netherlands Cancer Institute, Amsterdam, Netherlands )

Using combined oral contraceptives may decrease risk of Ovarian, Endometrial...

Dr Mustafa Kamani - Hacettepe University Faculty of Medicine, Ankara, Turkey

Using combined oral contraceptives may decrease risk of Ovarian, Endometrial and Colorectal cancer ( Dr Mustafa Kamani - Hacettepe University Faculty of Medicine, Ankara, Turkey )

More from ecancer